Autologous Anti-Claudin18.2 CAR T-cells LB1908

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CLDN18.2 CAR T-cells LB1908 specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - Autologous Anti-CLDN18.2 CAR T-cells LB1908 - Autologous Anti-Claudin18.2 CAR T Cells LB1908 - Autologous Claudin 18.2-targeting CAR-T Cells LB1908 - Claudin 18.2-targeted Autologous Chimeric Antigen Receptor T-cells LB1908 - LB 1908 - LB-1908 - LB1908